How a new approach to IP could have helped prevent COVID vaccine apartheid

Unfortunately, ensuring access to life-saving pharmaceuticals and health products for underserved communities and countries is often an afterthought, or non-existent priority for governments when they fund health innovation.

Moderna’s global rollout of its COVID vaccine would have looked very different if it had been subject to a strong and legally binding global access licence, helping to prevent the current vaccine apartheid that is inhibiting the world from getting beyond the COVID-19 pandemic, write Jocelyn Mackie and David Brook. Unsplash photograph by Ian Hutchinson

Opinion

BY JOCELYN MACKIE AND DAVID BROOK

November 24, 2021

A recent New York Times article, “Moderna and U.S. at Odds Over Vaccine Patent Rights,” highlights an all-too-common challenge in the world of public-private partnerships for ...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Weekend Point of View Newsletter

A round up of the past weekâ€™s opinion writers and columnists on Saturdays and Sundays.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy